...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Therapeutic advances in medical oncology. >Multi-institutional prospective study of nedaplatin plus S-1 chemotherapy in recurrent and metastatic nasopharyngeal carcinoma patients after failure of platinum-containing regimens
【24h】

Multi-institutional prospective study of nedaplatin plus S-1 chemotherapy in recurrent and metastatic nasopharyngeal carcinoma patients after failure of platinum-containing regimens

机译：含铂方案失败后复发和转移性鼻咽癌患者中奈达铂联合S-1化疗的多机构前瞻性研究

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

In this multi-institutional prospective study, we aimed to assess the safety and efficacy of nedaplatin plus S-1 (NS) chemotherapy for patients with recurrent and metastatic nasopharyngeal carcinoma (NPC) when platinum-containing regimens failed. A total of 52 recurrent and metastatic NPC patients who previously received, but failed with platinum-containing chemotherapy, had oral S-1 chemotherapy (twice daily from the first day to the fourteenth day) and nedaplatin (80 mg/ m2, day 1) every 3 weeks. The body surface area (BSA) decided the dose of S-1: 40 mg twice a day when BSA 2; 50 mg twice daily when 1.25 m2 ? BSA 2; and 60 mg twice daily when BSA ? 1.5 m2. Treatment was well tolerated. The main hematological adverse event was neutropenia. Five patients (9.6%) had grade 3 neutropenia. Three patients were found with grade 3 anemia (5.8%). One patient was found with grade 3 thrombocytopenia (1.9%). No patient was found with grade 3 or 4 nonhematological toxicity. The rates of complete response, partial response and overall response were 3.8%, 38.5% and 42.3%, respectively. Median time to progression was 6.2 months and median survival was 14.6 months. The rates of 1-year survival and 2-year survival were 63% and 27%, respectively. NS chemotherapy provides a satisfactory and safe clinical activity for patients with recurrent and metastatic NPC after platinum-containing chemotherapy failed.
机译：在这项多机构前瞻性研究中，我们旨在评估奈达铂加S-1（NS）化疗对含铂方案无效的复发和转移性鼻咽癌（NPC）患者的安全性和有效性。共有52例先前接受过但因含铂化疗失败而复发和转移的NPC患者，接受了口服S-1化疗（从第一天到第14天每天两次）和奈达铂（80 mg / m 2） ，第1天），每3周一次。体表面积（BSA）决定了S-1的剂量：当BSA 2 时，每天两次;两次40 mg。每天1.25 m 2 ≥50 mg BSA 2 ;每天两次，每次60毫克BSA吗？ 1.5 m 2 。治疗耐受性良好。主要的血液学不良事件是中性粒细胞减少。 5名患者（9.6％）患有3级中性粒细胞减少症。发现3例3级贫血（5.8％）。发现一名患者患有3级血小板减少症（1.9％）。没有患者被发现具有3或4级非血液学毒性。完全缓解率，部分缓解率和总体缓解率分别为3.8％，38.5％和42.3％。进展中位时间为6.2个月，中位生存时间为14.6个月。 1年生存率和2年生存率分别为63％和27％。含铂化疗失败后，NS化疗为复发性和转移性NPC患者提供了令人满意的安全临床活动。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号